Relief Therapeutics Holding AG (RLFTF)

[Pcilliterate]

Aquisition is a very likely scenario because acquisitions and Dr. Javitt go hand in hand. (Articles/bios written in different years explains varying #'s of successful acquisitions cited.) An acquisition in and of itself is not necessarily a bad thing, depending on timing. If it occurs after FDA approval, we could be big winners. If it occurs before, smaller winners.

https://orcid.org/0000-0003-2371-1609

Jonathan has been a founder of 6 health informatics and analytics companies that have gone on to successful public acquisitions: Healthcare Computer Associates (NYSE: SMSI), NextGen (Nasdaq:QSII), Certitude (NYSE:UNH), Active Health Management (NYSE:UNH), First Gateways (NYSE:DGX) and Coderyte, Inc., (NYSE:3M), and Telcare, Inc., funded by Qualcomm Ventures, Sequoia Capital, and Norwest Venture Partners. Most recently, he has founded NeuroRx, Inc., a clinical stage pharmaceutical company targeting the brain’s NMDA receptor for treatment of acute suicidal crisis in patients with depression.

https://www.neurorxpharma.com/about-us/#1595800169714-df900b26-e0f6

Dr. Javitt has played leadership roles in seven successful healthcare IT and biopharma startups with public exits. He has additionally led drug-development engagements for Merck, Allergan, Pharmacia, Novartis, and Pfizer.

https://www.crunchbase.com/person/jonathan-c-javitt

is a physician with expertise in information technology, health economics, and public health. He has been a founder of health information technology companies that have become part of Siemens, Inc., United Health Group, Inc., and Aetna, Inc. In 1994 he founded Certitude, Inc., which was acquired by United Health Care (NYSE:UNH) as part of the Ingenix formation. Following a term of service as Senior VP and National Medical Director, he left to co-found eMEDx, Inc., which became part of Active Health Management. Dr. Javitt served as Chief Scientific Officer of Active Health until its acquisition by Aetna (NYSE:AET).

He went on to serve as a member of the Office of the CEO and Chairman of FCG, Inc. as a lead architect of the Gateways offering, which was acquired by Quest Diagnostics (NYSE:DGX). He has played a leading role in pharmaceutical and medical device development teams at Merck, Allergan, Alcon, and Pfizer.